Leap Therapeutics, Inc.
LPTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1,500 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $427 | $0 | $0 |
| Gross Profit | $0 | -$427 | $0 | $1,500 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $57,211 | $73,234 | $44,965 | $32,160 |
| G&A Expenses | $12,846 | $13,807 | $11,798 | $10,766 |
| SG&A Expenses | $12,846 | $13,380 | $11,798 | $10,766 |
| Sales & Mktg Exp. | $0 | -$427 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $70,057 | $86,614 | $56,763 | $42,926 |
| Operating Income | -$70,057 | -$87,041 | -$56,763 | -$41,426 |
| % Margin | – | – | – | -2,761.7% |
| Other Income/Exp. Net | $3,087 | $5,627 | $2,314 | $815 |
| Pre-Tax Income | -$66,970 | -$81,414 | -$54,449 | -$40,611 |
| Tax Expense | $585 | $0 | $147 | -$24 |
| Net Income | -$67,555 | -$81,414 | -$54,596 | -$40,587 |
| % Margin | – | – | – | -2,705.8% |
| EPS | -1.81 | -3.98 | -4.82 | -4.73 |
| % Growth | 54.5% | 17.4% | -1.9% | – |
| EPS Diluted | -1.81 | -3.98 | -4.82 | -4.73 |
| Weighted Avg Shares Out | 37,551 | 20,445 | 11,324 | 8,583 |
| Weighted Avg Shares Out Dil | 37,551 | 20,445 | 11,324 | 8,583 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,129 | $4,027 | $925 | $9 |
| Interest Expense | $0 | $0 | $54 | $41 |
| Depreciation & Amortization | $5 | $427 | $16 | $29 |
| EBITDA | -$70,052 | -$80,987 | -$54,379 | -$40,541 |
| % Margin | – | – | – | -2,702.7% |